Q2 EPS Estimates for TerrAscend Raised by Atb Cap Markets

Key Points

• Atb Cap Markets has upgraded its Q2 2025 EPS estimate for TerrAscend Corp. from ($0.03) to ($0.02) per share, maintaining a "Strong-Buy" rating on the stock.
• Despite the upgrade, TerrAscend reported a quarterly EPS of ($0.03), missing analysts' expectations by ($0.01) during their latest earnings announcement.
• As of now, TerrAscend's stock is trading at $0.51, with a market capitalization of $156.12 million and a 52-week trading range between $0.23 and $1.75.

TerrAscend Corp. (OTCMKTS:TSNDF - Free Report) - Atb Cap Markets upped their Q2 2025 earnings estimates for TerrAscend in a report released on Tuesday, August 5th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings per share of ($0.02) for the quarter, up from their prior estimate of ($0.03). Atb Cap Markets currently has a "Strong-Buy" rating on the stock. The consensus estimate for TerrAscend's current full-year earnings is ($0.14) per share.

TerrAscend Stock Performance

OTCMKTS TSNDF traded up $0.02 on Friday, reaching $0.77. 1,061,898 shares of the company's stock traded hands, compared to its average volume of 638,590. The firm has a market cap of $235.68 million, a price-to-earnings ratio of -1.88 and a beta of 1.39. The stock has a 50 day moving average price of $0.35 and a 200-day moving average price of $0.40. TerrAscend has a fifty-two week low of $0.23 and a fifty-two week high of $1.75. The company has a debt-to-equity ratio of 1.94, a quick ratio of 1.07 and a current ratio of 1.45.

TerrAscend (OTCMKTS:TSNDF - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The business had revenue of $65.01 million for the quarter, compared to analyst estimates of $64.87 million. TerrAscend had a negative net margin of 40.86% and a negative return on equity of 23.19%.

About TerrAscend

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names.